Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,852Revenue $M4.8Net Margin (%)-3,587.7Z-Score1.5
Enterprise Value $M2,769EPS $-1.7Operating Margin %-3,549.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.3Pre-tax Margin (%)-3,587.7Higher ROA y-yY
Price/Book10.510-y EBITDA Growth Rate %-21.7Quick Ratio8.6Cash flow > EarningsY
Price/Sales7625-y EBITDA Growth Rate %-21.1Current Ratio8.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-25.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-57.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M113ROI % (ttm)-32.8Gross Margin Increase y-yN

Gurus Latest Trades with THRX

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THRXSeth Klarman 2014-03-31 Add0.42%$24.31 - $32.63
($29.32)
$ 25.32-14%Add 2.79%20,705,801
THRXSeth Klarman 2013-12-31 Add1.65%$27.19 - $32.81
($29.19)
$ 25.32-13%Add 8.83%20,144,301
THRXJean-Marie Eveillard 2013-12-31 Add0.03%$27.19 - $32.81
($29.19)
$ 25.32-13%Add 23.4%1,509,404
THRXSeth Klarman 2013-09-30 Add2.3%$28.86 - $34.36
($31.06)
$ 25.32-18%Add 11.92%18,510,371
THRXSeth Klarman 2013-06-30 Add2.85%$18.15 - $33.74
($26.83)
$ 25.32-6%Add 22.02%16,538,977
THRXJean-Marie Eveillard 2013-06-30 Add0.08%$18.15 - $33.74
($26.83)
$ 25.32-6%Add 139.14%1,109,620
THRXJean-Marie Eveillard 2012-06-30 Add0.01%$14.11 - $19.04
($16.72)
$ 25.3251%Add 24.23%509,710
THRXSeth Klarman 2012-03-31 Add0.22%$13.21 - $16.28
($13.91)
$ 25.3282%Add 2.3%14,553,800
THRXJean-Marie Eveillard 2012-03-31 Add0.01%$13.21 - $16.28
($13.91)
$ 25.3282%Add 25.59%410,310
THRXSeth Klarman 2011-09-30 Add0.84%$14.05 - $20.04
($16.74)
$ 25.3251%Add 9.76%14,225,961
THRXJulian Robertson 2011-09-30 Sold Out -1.2512%$14.05 - $20.04
($16.74)
$ 25.3251%Sold Out0
THRXJohn Griffin 2011-06-30 Sold Out $17.07 - $23.13
($20)
$ 25.3227%Sold Out0
THRXJean-Marie Eveillard 2011-06-30 Reduce-0.02%$17.07 - $23.13
($20)
$ 25.3227%Reduce -33.79%326,710
THRXJean-Marie Eveillard 2011-03-31 Add0.02%$16.91 - $20.77
($18.79)
$ 25.3235%Add 51.02%493,410
THRXWilbur Ross 2011-03-31 Sold Out $16.91 - $20.77
($18.79)
$ 25.3235%Sold Out0
THRXJulian Robertson 2011-03-31 Reduce-0.35%$16.91 - $20.77
($18.79)
$ 25.3235%Reduce -20.94%211,686
THRXWilbur Ross 2010-12-31 Buy 0.13%$16.12 - $23.08
($18.83)
$ 25.3234%New holding, 45219 sh.45,219
THRXJulian Robertson 2010-09-30 Buy 1.94%$9.53 - $16
($11.92)
$ 25.32112%New holding, 287763 sh.287,763
THRXJohn Griffin 2010-06-30 Buy 0.14%$10.09 - $13.82
($11.81)
$ 25.32114%New holding, 620000 sh.620,000
THRXSeth Klarman 2010-03-31 Add2.36%$7.82 - $11.16
($9.77)
$ 25.32159%Add 28.71%13,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
THRX Jean-Marie Eveillard 2014-03-311,595,5201.420.13+5.71%
THRX Seth Klarman 2014-03-3120,705,80118.3815.5+2.79%
Premium Most recent portfolio changes are included for Premium Members only!


THRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2014-05-09Buy317,770$8544840-100view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2014-03-03Sell65,806$36.73-24.29view
Mammen MathaiSVP, Research & Early Clin Dev 2014-02-14Sell35,000$39.36-29.34view
GLAXOSMITHKLINE PLC10% Owner 2014-02-11Buy342,229$12850700-100view
GLAXOSMITHKLINE PLC10% Owner 2013-10-29Buy130,473$4913610-100view
Winningham Rick ECEO 2013-09-12Sell22,353$40.03-30.53view
Mammen MathaiSVP, Research & Early Clin Dev 2013-07-30Sell7,000$36.51-23.83view
GLAXOSMITHKLINE PLC10% Owner 2013-07-30Buy3,064,407$111851000-100view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2013-06-07Sell31,038$35.04-20.63view
Brinkley David LHead of Business Dev. 2013-05-29Sell3,808$35.01-20.57view

Press Releases about THRX :

    Quarterly/Annual Reports about THRX:

    News about THRX:

    Articles On GuruFocus.com
    Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
    Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
    Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
    Top Four from Baupost’s Seth Klarman Jul 18 2013 
    What Can We Earn If We Invest in the Top Five Holdings of the Baupost Group? May 29 2013 
    Weekly CEO Sells Highlight: Texas Roadhouse Inc., Theravance Inc., AmerisourceBergen Corp. and Nuanc May 06 2013 
    WEEKLY CFO SELLS HIGHLIGHT: THRX, BERY, IPG, PG, ZNGA, TSS May 05 2013 
    Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
    Weekly CFO Sells Highlight: CMCSA, ACTU, FRGI, PETM, THRX, DXPE, CRZO Jun 04 2012 
    sk adding May 12 2012 


    More From Other Websites
    UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On Value Jul 21 2014
    Theravance/Glaxo Commence Global Late stage Study on COPD Jul 16 2014
    THERAVANCE INC Files SEC form 8-K, Other Events Jul 16 2014
    GSK and Theravance announce initiation of phase III programme with fixed dose triple combination... Jul 16 2014
    GSK and Theravance Announce Initiation of Phase III Programme With Fixed Dose Triple Combination... Jul 16 2014
    Break Up Bonanza Jul 09 2014
    THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 09 2014
    Glaxo/Theravance Drug Gets Japanese Approval Jul 07 2014
    THERAVANCE INC Files SEC form 8-K, Other Events Jul 07 2014
    Glaxo, Theravance announce Japanese approval for Anoro Ellipta Jul 07 2014
    Anoro(R) Ellipta(R) (Umeclidinium/Vilanterol) Gains Approval in Japan for the Treatment of COPD Jul 07 2014
    Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, Corporate Partnerships, Clinical And... Jul 02 2014
    Theravance, Inc. Appoints Theodore J. Witek, Jr. as Senior Vice President, Corporate Partnerships,... Jul 02 2014
    THERAVANCE INC Files SEC form 8-K, Other Events Jul 02 2014
    Glaxo/Theravance Seek to Expand Breo Ellipta's Label Jul 01 2014
    Why Theravance (THRX) Could Be Positioned for a Surge? Jul 01 2014
    THERAVANCE INC Files SEC form 8-K, Other Events Jun 30 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide